... Show More
0.00 -
This Year’s Performance. Risk Score Considers Last 7D.
Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
Dear Investors, Here is your monthly update for August 2018 The CRISPR-Tech CopyFund is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology. This CopyFund’s portfolio is built by eToro’s investment committee. The S&P500 is currently up 10% this year. This CopyFund’s portfolio is currently up 15%, outperforming the index by 50%. This month was a strong month for the CopyFund closing at a significant profit of 11%. This CopyFund is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk remained the same for this CopyFund over last month. As published last month you can read about CRISPR technology and its growth potential here: <a href="" class="e-link" target="_blank" rel="noopener noreferrer"></a> As this is as a relatively emerging market and some of the stocks have a smaller market cap compared to others, increaed volatility in this portfolio is possible. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. Similar to blokchain the stocks in this portfolio are competing to be the market leader in a new emerging industry. This portfolio provides investors diversification among this sector and protects them from losses if one specific stock they preferred was to suffer losses. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. Some clients have already added the <a href="/people/cannabiscare" class="e-link">@CannabisCare</a> investment strategy to their watchlist, another bio-tech portfolio. Further communications around the opening of this portfolio will be made in due course. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, <a href="/markets/regn" class="e-link">$REGN (Regeneron Pharmaceuticals)</a> ... Show More